Anti-PD-L1 immunotherapy enhances radiation-induced abscopal response in glioblastoma

By News Release


Winner of the Ronald L. Bittner Award on Brain Tumor Research, Chibawanye Ene, MD, PhD, (pictured left) presented his research, Anti-PD-L1 Immunotherapy Enhances Radiation-induced Abscopal Response in Glioblastoma, during the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting held April 13-17 in San Diego.

Immunotherapy for glioblastoma has been largely unsuccessful, in part, because molecular heterogeneity drives selective elimination of only a subset of tumor cells. It appears that therapeutic success in patients will require achieving an abscopal effect, where following focused radiation therapy, non targeted tumor cells are attacked by the immune system. It remains unclear how glioblastoma respond to focused radiation in terms of failure location and whether immunotherapy could amplify the immune response to tumor outside the radiation field.

The result of the study’s experiment show that radiation combined with anti PD L1 therapy induces an immunological response to unirradiated glioblastoma. The researchers are currently optimizing other treatment combinations that could also be readily assessed in phase I human clinical trials.

Author Block: Chibawanye Ene, MD, PhD (Seattle); Shannon Kreuser; Miyeon Jung; Ian Parney; Courtney Crane; Eric Holland

Disclosure: The author reported no conflicts of interest.

Back To Top

Anti-PD-L1 immunotherapy enhances radiation-induced abscopal response in glioblastoma.  Appl Rad Oncol. 

By News Release| April 16, 2019

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

    Agility CMS